AGM Statement

Provexis PLC
23 August 2005



                                  Provexis plc

                                  AGM STATEMENT


Dawson Buck, Chairman of Provexis plc, will make the following statement at 
today's Annual General Meeting ('AGM'):

'Provexis plc was admitted to trading on AIM exactly two months ago. This was 
the coming together of two businesses, Provexis Limited and Nutrinnovator 
Holdings plc, with the shared vision of creating a company which is now uniquely 
differentiated in the functional food market.

Subsequently, I am delighted to report that the integration has gone extremely
well and the new team has a clear, shared energy and commitment to the future
success of Provexis plc.

Our lead product, SircoTM, is a fruit juice drink that contains a patented
bioactive extract from tomatoes (called FruitflowTM). It has been proven in
human trials to inhibit blood platelet aggregation and thereby reduce the risk
of thrombosis, the primary cause of heart attack and stroke. SircoTM, which
carries a health claim, is uniquely positioned in the heart health category due
to its function and the immediacy of the benefit.

Earlier this month we announced a three-year agreement with the registered heart
health charity, H-E-A-R-T UK, for SircoTM, which provides us with formal
approval and endorsement of the product.

Due to the high level of interest from a number of the major UK supermarkets and
other key high street retailers, we are now planning a much larger distribution
base at launch, supported by a nationwide marketing campaign in early 2006.

Both the supermarkets and the retailers have indicated that maximum impact will
be made by a launch in the post-Christmas period, when health and wellbeing is
at its highest on the consumer's personal agenda. We will therefore be launching
SircoTM in January 2006.

Whilst the current focus is working towards the launch of SircoTM the R&D
pipeline, in conjunction with our technology partners, continues to progress.
This includes the functional fruit juice beverage which will contain a
proprietary extract from broccoli proven to reduce the risk of specific cancers
and the medical food for the dietary management of Crohn's Disease. The Board
continues to monitor the Altu food bar and is considering its future strategy in
relation to this product.

Provexis plc has made a positive start since admission to AIM in June and the 
Company is now gearing up to the launch of SircoTM in January 2006. I look 
forward to reporting further progress in due course.'


Ends


For further information:

Provexis plc
Dr Stephen Franklin, CEO                 07710 348 774

Bell Pottinger Corporate and Financial
Ann-Marie Wilkinson/Emma Kent            020 7861 3232




                      This information is provided by RNS
            The company news service from the London Stock Exchange